Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690961 | 0.80 | CYP2B6 (0.42) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6266959 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL27687452 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6419763 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Magnesium SCHEMBL9492700 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2514484 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL27994723 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Magnesium SCHEMBL4423652 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL28896760 | 0.78 | CYP2B6 (0.41) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL9208 | 0.77 | CYP2B6 (0.43) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044779-B | Organic electron transport material containing benzodioxan and application thereof | 上海传勤新材料有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-114044779-A | Organic electron transport material containing benzodioxan and application thereof | 上海传勤新材料有限公司 | 2022-02-15 | — | — | CN | claimed |
| WO-2021132627-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | 大日本住友製薬株式会社 | 2021-07-01 | — | — | WO | claimed |
| EP-3206660-B1 | MALODOR REDUCING COMPOSITIONS | GIVAUDAN SA (CH) | 2021-03-31 | — | — | EP | claimed |
| US-20170290757-A1 | MALODOR REDUCING COMPOSITIONS | GIVAUDAN S.A. (CH) | 2017-10-12 | — | — | US | claimed |
| EP-3206660-A1 | MALODOR REDUCING COMPOSITIONS | Givaudan S.A. (CH) | 2017-08-23 | — | — | EP | claimed |
| WO-2016058710-A1 | MALODOR REDUCING COMPOSITIONS | GIVAUDAN SA (CH) | 2016-04-21 | — | — | WO | claimed |
| CN-105473641-A | Method for preparing dioxyheterocycle-based electrochromic polymers | UNIV FLORIDA | 2016-04-06 | — | — | CN | claimed |
| EP-1933622-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | claimed |
| US-9180192-B2 | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-11-10 | — | — | US | claimed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050203069-A1 | Nitric oxide-releasing molecules | NOXILIZER, INC. | 2005-09-15 | — | — | US | claimed |
| WO-2005081752-A2 | NITRIC OXIDE-RELEASING POLYMERS | AMULET PHARMACEUTICALS, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| WO-2005081753-A2 | NITRIC OXIDE-RELEASING MOLECULES | NOXILIZER, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | claimed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | claimed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | claimed |
| US-5225427-A | 10-substituted ether derivatives of dihydroartemisinin, process for their preparation and their use as antiprotozoal agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203069-A1 | Nitric oxide-releasing molecules | NOS2, NOS1, NOS3 | KDM4E 3118/4885MEN1 738/4885ALDH1A1 2203/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | KDM4E 4541/4885MEN1 1518/4885ALDH1A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.